Latest news with #AstraZenecaPharma
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
AstraZeneca Pharma shares surge 12% after Q4 results; profit jumps 48%
Shares of AstraZeneca Pharma India rallied nearly 12 per cent on Monday after its net profit for the fourth quarter of the previous financial year (Q4 FY25) jumped 48 per cent to ₹58.25 crore year-on-year (Y-o-Y). The pharma major's stock rose as much as 11.87 per cent during the day to ₹8,919 per share, the biggest intraday gain since March 20 this year. The stock pared gains to trade 11.2 per cent higher at ₹8,875 apiece, compared to a 0.54 per cent decline in Nifty50 as of 10:54 AM. Shares of the company extended gains to their third day while they have fallen 21 per cent this year, compared to a 4.1 per cent advance in the benchmark Nifty50. AstraZeneca Pharma has a total market capitalisation of ₹22,195.5 crore, according to BSE data. Track LIVE Stock Market Updates Here AstraZeneca Pharma Q4 results The pharma major reported a 48 per cent rise in consolidated net profit for Q4 FY24 to ₹58.25 crore. Total revenue from operations stood at ₹480.48 crore, up 25.3 per cent Y-o-Y. The company also recorded significant growth across therapeutic areas, achieving a 32 per cent increase in full-year revenue compared to the previous year. In its oncology business, the pharma major reported revenue of ₹315.85 crore in Q4FY25, a rise of 31.62 per cent. Additionally, revenue from biopharmaceuticals (cardiovascular, renal and metabolism; respiratory and immunology; and vaccines and immune therapies) rose 1.9 per cent to ₹122.74 crore. The rare disease segment grew to Rs 2 crore in Q4FY25, up from Rs 0.17 crore in Q4FY24. AstraZeneca Pharma management commentary 'FY2024–25 marked significant progress for AstraZeneca Pharma India Limited, driven by strong growth of 32 per cent," said Bhavana Agrawal, Chief Financial Officer and Director, AstraZeneca Pharma. "This reflects our strategic focus on science, specialists, and the strength of our innovation-led portfolio. As we scale impact across therapy areas, we remain committed to delivering sustainable value to the people, society, and the planet.' About AstraZeneca Pharma AstraZeneca Pharma is a British-Swedish multinational pharmaceutical and biotechnology company, formed in 1999 through the merger of Sweden's Astra AB and Britain's Zeneca Group. The company is dedicated to developing and selling innovative medicines across various therapeutic areas, including cancer, cardiovascular diseases, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation. The company has had a major presence in India for 45 years. AstraZeneca Pharma India oversees manufacturing, sales, and marketing operations, while the company also gained global recognition for its role in developing the Oxford–AstraZeneca Covid–19 vaccine
Business Standard
5 days ago
- Business
- Business Standard
AstraZeneca Pharma soars after Q4 PAT jumps 48% YoY
AstraZeneca Pharma surged 10.03% to Rs 8764.05 after the company's standalone net profit rose 47.54% to Rs 58.25 crore, while revenue from operations rose 25.39% to Rs 480.48 crore in Q4 March 2025 over Q4 March 2024. Profit before tax (PBT) stood at Rs 78.47 crore in Q4 FY25, up 44.35% year-on-year, and up 86.74% quarter-on-quarter. Total expenses rose 22.22% to Rs 412.48 crore in Q4FY25 over Q4FY24. During the quarter, cost of materials consumed stood at Rs 94.25 crore (up 180.34% YoY) while employee benefits expense was at Rs 66.07 crore (up 13.95% YoY). The company's net profit surged 88.82% while net sales rose 9.13% in Q4 March 2025 over Q3 December 2024. For the full year FY25, revenue from operations rose 32.48% to Rs 1,716.29 crore, while net profit fell 28.34% to Rs 115.74 crore. PBT fell 28.78% to Rs 156.36 crore compared to FY24. The company's standalone net cash from operating activities stood at Rs 65.36 crore in FY25, as against Rs 27.87 crore in FY24. Dr. Sanjeev Panchal, country president & managing director of the company, said, "Our company delivered strong growth in Financial Year 2024-25 by launching innovative medicines in India, giving us momentum into 2025 and beyond. We are pleased to share that our company has, for the first time, crossed the INR 1,700 crore mark ($200 million)." The board recommended dividend of Rs 32 per equity share for FY25. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.
&w=3840&q=100)
Business Standard
30-05-2025
- Business
- Business Standard
AstraZeneca Pharma rises 2% on securing CDSCO nod for Benralizumab solution
AstraZeneca Pharma share price: Pharmaceutical company AstraZeneca shares rose as much as 2.14 per cent to hit an intraday high of ₹8,089 per share on the last trading day of the week i.e. Friday, May 30, 2025. At 1:30 PM, AstraZeneca Pharma shares were trading 1.26 per cent higher at ₹8,018.90 per share. By comparison, the BSE Sensex was trading 0.21 per cent lower at 81,461.57 levels. Why did AstraZeneca share price rise in trade today? AstraZeneca Pharma share price rose after it received approval from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India, to import for sale and distribution of Benralizumab 30 mg/ml solution for injection (brand name: Fasenra) for an additional indication. In an exchange filing, AstraZeneca Pharma said, 'This is to inform that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Benralizumab 30 mg/ml Solution for Injection (Brand name: Fasenra) for an additional indication.' Benralizumab is used as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Besides, the approval also paves way for the marketing of Benralizumab 30 mg/ml solution for injection (Brand name: Fasenra) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any. Earlier this week, AstraZeneca Pharma India secured approval from CDSCO to import for sale and distribution of Osimertinib Tablets 40 mg & 80 mg (TAGRISSO) for an additional indication. Osimertinib as monotherapy is used in the treatment of patients with locally advanced, unresectable (stage III) NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, and whose disease has not progressed during or following platinum-based chemoradiation therapy AstraZeneca Pharma Q4 results The Board of Directors of AstraZeneca Pharma will meet today to consider and approve the March quarter of financial year 2025 (Q4FY25) and financial year 2025 (FY25) results, along with dividend for FY25, if any. About AstraZeneca Pharma AstraZeneca Pharma is a British-Swedish multinational pharmaceutical and biotechnology company, formed in 1999 through the merger of Sweden's Astra AB and Britain's Zeneca Group. The company is dedicated to developing and selling innovative medicines across various therapeutic areas, including cancer, cardiovascular diseases, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation. The company has had a major presence in India for 45 years. AstraZeneca Pharma India oversees manufacturing, sales, and marketing operations, while the company also gained global recognition for its role in developing the Oxford–AstraZeneca Covid-19 vaccine Leveraging data science and artificial intelligence (AI), AstraZeneca claims to boost the success rates and efficiency of its research and development (R&D) processes. The market capitalisation of AstraZeneca Pharma is ₹20,037.38 crore, according to BSE. The company falls under the BSE500 index. The 52-week high of AstraZeneca share price is ₹9,199, while its 52-week low is ₹5,415.55.
Mint
30-05-2025
- Business
- Mint
Q4 results today: Vodafone Idea, Nykaa, Apollo Hospitals, Sun TV Network and others to declare earnings on May 30
Q4 results today: As the Q4 earnings season enters the final leg, more than 800 companies are scheduled to announce financial results on Friday, May 30, 2025, including firms such as Vodafone Idea, FSN-E-Commerce, Apollo Hospitals Enterprises, AstraZeneca Pharma, and Sun TV Network. Here is a list of some of the major companies expected to report earnings on Friday, May 30, 2025, according to the BSE calendar. Bajaj Holdings & Investment, Apollo Hospitals Enterprises, Vodafone Idea, FSN E-Commerce Ventures (Nykaa), Sun TV Network, Inox Wind, PTC Industries, AstraZeneca Pharma, Inox Wind Energy, Swan Energy, Ingersoll Rand (India), Titagarh Rail Systems, Genus Power Infrastructures, Ramkrishna Forgings, Valor Estate, Kama Holdings, PNC Infratech, Greenlam Industries, Inox Green Energy Services, Ahluwalia Contracts India, Indo Count Industries, Puravankara, Diamond Power Infrastructure, India Tourism Development Corporation, National Fertilizers, Rolex Rings, FIEM Industries, Kiri Industries, TCPL Packaging, Easy Trip Planners, Ashapura Minechem, Gufic Biosciences. Lancer Containers Lines, Jamna Auto Industries, Marsons, Sindhu Trade Links, Panacea Biotech, Ashiana Housing, Genesys International Corporation, Pennar Industries, TCI Express, La Opala RG, Spectrum Electrical Industries, SML Isuzu, SMS Pharmaceuticals, Indo Thai Securities, Rane Holdings, Spandana Sphoorty Financial, Sigachi Industries, Jai Corp, Rama Steel Tubes, Divgi Torqtransfer Systems, Sanstar Knowledge Marine & Engineering Works, Algoquant Fintech, BL Kashyap & Sons, India Nippon Electricals, Salasar Techno Engineering, MSP Steel & Power, AMIC Forging, Panorama Studios International, Praveg, Renaissance Global, Heubach Colorants India, Kellton Tech Solutions. OM Infra, Allied Digital Services, Asian Star Signpost India, Prakash Pipes Limited, Garuda Construction and Engineering, Sree Rayalaseema Hi Strength Hypo, NCL Industries, Fedders Holding, Bigbloc Construction, Max India Limited, Hazoor Multi Projects, Shivalik Rasayan, Eraaya Lifespaces, Sasta Sundar Ventures, Swelect Energy Systems, Dharmaj Crop Guard, Pakka, Ganesh Infraworld, GFL, Hampton Sky Realty, Empire Industries, Last Mile Enterprises, Delton Cables, Deepak Builders & Engineers India, Sarveshwar Foods,nGVK Power & Infrastructure, Hardwyn India, Sukhjit Starch and Chemicals, Primo Chemicals, KN Agri Resources, MK Ventures Capital, Avonmore Capital & Management Services, Nectar Lifesciences, Uravi Defence and Technology, Utssav CZ Gold Jewels, SKM Egg Products Export (India), Nahar Industrial Enterprises, Vardhman Polytex, Medicamen Biotech, Sunrakshakk Industries India. Vashu Bhagnani Industries, Swaraj Suiting, Madhuveer Com 18 Network, Jyothi Infraventures, MBL Infrastructure, Artificial Electronics Intelligent Material, Veljan Denison, Valiant Communications, Atmastco, Mini Diamonds (India), Sakuma Exports, Ind-Swift Laboratories, Spacenet Enterprises India, Race Eco Chain, Fluidomat, Xtglobal Infotech, IZMO, Nova Agritech, UVS Hospitality and Services, Commercial Syn Bags, AVG Logistics, Filatex Fashions, Osia Hyper Retail, Innovators Facade Systems, Supreme Holdings & Hospitality and Gujarat Apollo Industries.
